Stockscreener 앱 받기
3.15
3.96%
0.12
전일 마감가:
$3.03
열려 있는:
$3.05
하루 거래량:
15,835
Relative Volume:
0.30
시가총액:
$217.87M
수익:
$64.49M
순이익/손실:
$-71.40M
주가수익비율:
-2.8899
EPS:
-1.09
순현금흐름:
$-52.00M
1주 성능:
-3.37%
1개월 성능:
+14.13%
6개월 성능:
-16.00%
1년 성능:
-37.00%
1일 변동 폭
$3.05
$3.1888
1주일 범위
$2.981
$3.33
52주 변동 폭
$2.58
$6.28
Sophia Genetics Sa Stock (SOPH) Company Profile
SOPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SOPH
Sophia Genetics Sa
|
3.15 | 217.87M | 64.49M | -71.40M | -52.00M | -1.09 |
|
VEEV
Veeva Systems Inc
|
238.27 | 36.73B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.28 | 10.64B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
54.80 | 9.30B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
92.59 | 7.43B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
41.20 | 6.34B | 906.14M | -52.62M | 89.62M | -0.3621 |
Sophia Genetics Sa Stock (SOPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Craig Hallum | Buy |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | Guggenheim | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-03 | 개시 | BTIG Research | Buy |
| 2022-11-23 | 개시 | Credit Suisse | Neutral |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-17 | 개시 | Cowen | Outperform |
| 2021-08-17 | 개시 | Credit Suisse | Outperform |
| 2021-08-17 | 개시 | JP Morgan | Overweight |
| 2021-08-17 | 개시 | Morgan Stanley | Overweight |
모두보기
Sophia Genetics Sa 주식(SOPH)의 최신 뉴스
Sophia Genetics SA expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Promising Penny Stocks To Consider In April 2025 - simplywall.st
SOPHia Genetics expands testing partnership with AstraZeneca - MSN
SOPHiA Genetics (SOPH) Expands Liquid Biopsy Collaboration with AstraZeneca - GuruFocus
SOPHiA GENETICS Expands Global Collaboration With AstraZeneca To Advance Liquid Biopsy Testing - Nasdaq
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR – Company AnnouncementFT.com - Financial Times
SOPHiA GENETICS and AstraZeneca Scale Breakthrough Liquid Biopsy Testing to 30 Global Centers - Stock Titan
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR - Barchart.com
SOPHiA GENETICS SA's (NASDAQ:SOPH) market cap touched US$204m last week, benefiting both individual investors who own 51% as well as institutions - simplywall.st
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 - marketscreener.com
SOPHiA GENETICS Q1 2025 Earnings: AI Healthcare Leader Reports Financial Results May 6 - Stock Titan
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatili - GuruFocus
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatility - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities - MarketScreener
SOPHiA GENETICS Partners With Precision for Medicine - marketscreener.com
Major AI Breakthrough: SOPHiA GENETICS Partners to Transform Clinical Trial Analysis - Stock Titan
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities - MarketScreener
Precision Medicine Software Market: Global Expansion & Growth - openPR.com
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? - Yahoo Finance
Mesoblast (NASDAQ:MESO) & SOPHiA GENETICS (NASDAQ:SOPH) Financial Review - Defense World
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For - Simply Wall St
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC - Barchart
Two Use Cases for AI in Healthcare - Streetwise Reports
March 2025's Promising Penny Stocks To Consider - Simply Wall St
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Precision Medicine Software Market Set for Global Expansion - openPR.com
Sophia Genetics at TD Cowen Conference: AI-Powered Growth Strategy By Investing.com - Investing.com UK
SOPHiA GENETICS : To Present at the NVIDIA GTC AI Conference -March 06, 2025 at 05:30 am EST - Marketscreener.com
BTIG cuts Sophia Genetics stock price target to $5, maintains buy - Investing.com
Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Highlights: Record Customer Growth Amidst ... By GuruFocus - Investing.com Canada
SOPHiA GENETICS Reports 2024 Financial Results - TipRanks
SOPHiA GENETICS Earnings Call: Mixed Results, Optimistic Outlook - TipRanks
Sophia Genetics SA reports results for the quarter ended December 31Earnings Summary - TradingView
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Earnings call transcript: Sophia Genetics Q4 2024 sees slight EPS miss - Investing.com
SOPHiA GENETICS SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
SOPHiA GENETICS : Investor PresentationFebruary 2025 -March 04, 2025 at 06:53 am EST - Marketscreener.com
Sophia Genetics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results - PR Newswire
Principal Financial Group Inc. Sells 26,798 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
SOPHiA GENETICS (SOPH) to Release Quarterly Earnings on Tuesday - The AM Reporter
SOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing - PR Newswire
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing -February 24, 2025 at 04:01 am EST - Marketscreener.com
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing – Company Announcement - Financial Times
NeoGenomics plummets on Q4 2024 bottom line miss, soft EPS guidance - MSN
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 - Marketscreener.com
Sophia Genetics Sa (SOPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.12%
2.25%
자본화:
|
볼륨(24시간):